wish i was a medico, page-8

Thanks Milward, bit more info from that ann:

We remain encouraged that the study met its primary endpoint of achieving durable responses in patients with metastatic melanoma," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We missed statistical significance on the secondary endpoint of overall survival but the strong trend in survival benefit supports further research of talimogene laherparepvec to better understand its role in melanoma, both as a single-agent and in combination with other therapies."